Defining prostate specific antigen progression after radical prostatectomy: What is the most appropriate cut point?

Journal of Urology

Volumn 165, Issue 4, 2001, Pages 1146-1151

  Amling, Christopher L ^b   Bergstralh, Erik J ^b   Blute, Michael L ^b   Slezak, Jeffrey M ^b   Zincke, Horst ^b  

^a NAVAL MEDICAL CENTER SAN DIEGO   (United States)

^b NONE

Author keywords

Biochemical phenomena; Prostate specific antigen; Prostatectomy; Prostatic neoplasms; Recurrence

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER RECURRENCE; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; TECHNIQUE; TREATMENT FAILURE;

EID: 0035093811     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)66452-X     Document Type: Article

References (17)

1. Natural history of progression after PSA evaluation following radical prostatectomy
2. Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer
3. Black race is an adverse prognostic factor for prostate cancer recurrence following radical prostatectomy in an equal access health care setting
4. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer
5. Consensus statement: Guidelines for PSA following radiation therapy
6. Biochemical outcome following external beam radiation for T1-2 prostate carcinoma: The importance of achieving an undetectable nadir PSA
7. Post-treatment PSA < or = 0.2 ng/mL defines disease freedom after radiotherapy for prostate cancer using modern techniques
8. Prostate-specific antigen after radiation therapy. Prognosis by pretreatment level and post-treatment nadir
9. The fall and rise of prostate-specific antigen. Kinetics of serum prostate-specific antigen levels after radiation therapy for prostate cancer
10. Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy
11. Nonparametric estimation from incomplete observations
12. Analysis of survival by tumor response
13. Urinary prostate specific antigen levels: Role in monitoring the response of prostate cancer to therapy
14. Ultrasensitive assay of prostate-specific antigen used for the early detection of prostate cancer relapse and estimation of tumor-doubling time after radical prostatectomy
15. New biological functions of prostate-specific antigen?
16. Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer
17. Treatment options for localized prostate cancer based on pretreatment serum prostate specific antigen levels